Why did Boundless Bio's operating expenses surge in Q4 2024?

The operating expenses of Boundless Bio in Q4 2024 are not available. However, we can infer that the surge in operating expenses might be related to the company's ongoing efforts to advance its cancer therapies and the associated costs. Here are some points to consider: 1. **Clinical Trial Costs**: Boundless Bio is actively involved in advancing its cancer therapies, which involves significant investments in clinical trials. The costs associated with conducting clinical trials, including personnel, facilities, and materials, can be substantial and vary depending on the phase and scope of the trial. 2. **Research and Development**: As a biotech company, Boundless Bio likely incurs high research and development (R&D) expenses. These costs can include personnel salaries, laboratory supplies, and expenses related to designing and conducting experiments. R&D expenses are a critical component of operating expenses in the biotech industry. 3. **Facilities and Infrastructure**: Biotech companies often require specialized facilities and infrastructure to develop and manufacture their products. The costs associated with maintaining and operating these facilities can be significant, especially if they are dedicated to specialized processes like gene therapy drug production. 4. **Regulatory Compliance**: Biotech companies must comply with various regulatory requirements, which can involve substantial costs. These costs can include expenses related to obtaining necessary approvals, as well as ongoing compliance efforts to ensure that products meet safety and efficacy standards. In conclusion, the surge in operating expenses for Boundless Bio in Q4 2024 might be attributed to the company's ongoing efforts to advance its cancer therapies, which includes significant investments in clinical trials, research and development, facilities and infrastructure, and regulatory compliance.